FibroGen, now Kyntra Bio, reports biopharmaceutical developments centered on oncology, rare disease and anemia assets. Recurring updates cover FG-3246, a CD46-targeting antibody-drug conjugate in development for metastatic castration-resistant prostate cancer, and FG-3180, an associated CD46-targeted PET imaging agent. News also covers roxadustat, including its approvals for anemia in chronic kidney disease in multiple non-U.S. markets and its U.S. orphan drug designation for myelodysplastic syndromes.
Company updates also include financial results, conference presentations, regulatory communications, shareholder and governance matters, and corporate-status changes. Completed corporate actions include the sale of FibroGen China operations and the 2026 name and ticker transition from FibroGen and FGEN to Kyntra Bio and KYNB.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.